CTOs on the Move

Turning Point Therapeutics

www.tptherapeutics.com

 
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company`s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point`s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Ed Gemo
SVP/CIO Profile

Funding

Turning Point Therapeutics raised $45M on 05/23/2017
Turning Point Therapeutics raised $80M on 10/19/2018
Turning Point Therapeutics raised $202.5M on 09/16/2019
Turning Point Therapeutics raised $373.8M on 05/18/2020

Similar Companies

Ganix

Ganix is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aastrom

We are committed to helping people with severe, chronic cardiovascular diseases realize the promise of patient-specific, expanded multicellular therapy.

True North Therapeutics

True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The companys lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, renal, and neurological space. True North was formed in 2013 as a spin-out of iPierian.

Ansa Biotechnologies

Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods.

Opentrons Labworks

Opentrons Labworks, Inc., is a disruptive life science company leveraging its integrated lab platform to supercharge the pace of innovation in research and healthcare. Opentrons Labworks is the parent company to business units Opentrons Robotics and Neochromosome. Through Opentrons Robotics, thousands of institutions are automating R&D operations with flexible, easy-to-use liquid handling lab robots. Through Neochromosome, biopharma and biotech at large can benefit from our world-class genome-scale cell engineering solutions. Opentrons Robotics, a business unit of Opentrons Labworks, Inc., is the industry leader in flexible, user-friendly automation for life science labs. Our open-source ecosystem offers the scientific community the tools they need to automate experiments, share protocols and reproduce each other`s results. Opentrons robots can be found in thousands of academic, biopharma, synthetic biology and clinical research labs in more than 40 countries.